Literature DB >> 12438901

Microbicide efficacy and toxicity tests in a mouse model for vaginal transmission of Chlamydia trachomatis.

Sharon L Achilles1, Priya B Shete, Kevin J Whaley, Thomas R Moench, Richard A Cone.   

Abstract

BACKGROUND: Microbicides are being developed for woman-controlled protection against sexually transmitted diseases (STDs). GOAL: The goal of the study was to test candidate microbicides in a mouse model for preventing vaginal transmission of and for acute toxicity to columnar epithelium. STUDY
DESIGN: Progestin-sensitized CF-1 mice were treated vaginally with 50 microl of microbicide, followed either by vaginal inoculation with 10 ID(50) of serovar D or by examination of the epithelial surface for acute toxicity with a viability stain (ethidium homodimer-1).
RESULTS: Nonoxynol-9 (N9), sodium dodecyl sulfate (SDS), chlorhexidine digluconate, and BufferGel all provided significant though incomplete protection against vaginal transmission. Other candidates, all of which were effective in vitro, provided no vaginal protection: kappa-carrageenan, dextran sulfate, polystyrene sulfonate, Concanavalin A, wheat germ agglutinin, and agglutinin. The surface-active agents (N9, SDS, and chlorhexidine) caused significant acute epithelial toxicity: 3 days after chlorhexidine exposure, mice also had vaginal friability and markedly increased susceptibility to. BufferGel was the only candidate tested that was both protective and relatively nontoxic.
CONCLUSION: Microbicides can provide vaginal protection against in highly susceptible progestin-sensitized mice. Since N9 does not inactivate, it likely protects by killing target cells in the vagina. Despite the ability to both potently inactivate and kill target cells, two surface-active agents, SDS and chlorhexidine, failed to provide complete protection, a circumstance which emphasizes the importance of distributing microbicides to all susceptible surfaces.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12438901     DOI: 10.1097/00007435-200211000-00007

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  24 in total

1.  The microbicide tenofovir does not inhibit nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae in urine samples.

Authors:  Billie Jo Wood; Patricia Rizzo-Price; Jeff Holden; Andrew Hardick; Thomas C Quinn; Charlotte A Gaydos
Journal:  J Clin Microbiol       Date:  2007-12-05       Impact factor: 5.948

Review 2.  Non-specific microbicide product development: then and now.

Authors:  Joseph W Romano; Melissa Robbiani; Gustavo F Doncel; Thomas Moench
Journal:  Curr HIV Res       Date:  2012-01-01       Impact factor: 1.581

3.  Comparative safety evaluation of the candidate vaginal microbicide C31G.

Authors:  Bradley J Catalone; Tina M Kish-Catalone; Elizabeth B Neely; Lynn R Budgeon; Mary L Ferguson; Catherine Stiller; Shendra R Miller; Daniel Malamud; Fred C Krebs; Mary K Howett; Brian Wigdahl
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

4.  Mucus-penetrating nanoparticles for vaginal drug delivery protect against herpes simplex virus.

Authors:  Laura M Ensign; Benjamin C Tang; Ying-Ying Wang; Terence A Tse; Timothy Hoen; Richard Cone; Justin Hanes
Journal:  Sci Transl Med       Date:  2012-06-13       Impact factor: 17.956

5.  Optical coherence tomography for assessment of microbicide safety in a small animal model.

Authors:  Brent A Bell; Kathleen L Vincent; Nigel Bourne; Gracie Vargas; Massoud Motamedi
Journal:  J Biomed Opt       Date:  2013-04       Impact factor: 3.170

Review 6.  Vaginal microbicides and the prevention of HIV transmission.

Authors:  Blayne Cutler; Jessica Justman
Journal:  Lancet Infect Dis       Date:  2008-11       Impact factor: 25.071

7.  Chlamydia trachomatis laboratory strains versus recent clinical isolates: implications for routine microbicide testing.

Authors:  M C Skinner; W E Stamm; M L Lampe
Journal:  Antimicrob Agents Chemother       Date:  2009-02-02       Impact factor: 5.191

8.  Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.

Authors:  Bradley J Catalone; Tina M Kish-Catalone; Lynn R Budgeon; Elizabeth B Neely; Maelee Ferguson; Fred C Krebs; Mary K Howett; Mohamed Labib; Robert Rando; Brian Wigdahl
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

Review 9.  Mucus penetrating nanoparticles: biophysical tool and method of drug and gene delivery.

Authors:  Laura M Ensign; Craig Schneider; Jung Soo Suk; Richard Cone; Justin Hanes
Journal:  Adv Mater       Date:  2012-07-24       Impact factor: 30.849

10.  Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo.

Authors:  Qingguo Xu; Laura M Ensign; Nicholas J Boylan; Arne Schön; Xiaoqun Gong; Jeh-Chang Yang; Nicholas W Lamb; Shutian Cai; Tao Yu; Ernesto Freire; Justin Hanes
Journal:  ACS Nano       Date:  2015-08-31       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.